444

EXTENDING QUALITY IMPROVEMENT FOR PANCREATODUODENECTOMY WITHIN THE HIGH-VOLUME SETTING: THE EXPERIENCE FACTOR

Date
May 7, 2023
Explore related products in the following collection:

Society: SSAT

LIVE STREAM SESSION
Introduction. Microvascular invasion (MVI) is the main risk factor for overall mortality and recurrence after surgery for hepatocellular carcinoma (HCC). Its diagnosis can be made only postoperatively on the histological specimen. The aim of this preliminary study was to train machine-learning models to predict MVI on preoperative CT scan (fig.1).
Methods. Clinical data and 3-phases CT scans were retrospectively collected among 4 Italian centres. DICOM files were manually segmented to detect the liver and the tumor(s). An already available segmentation algorithm (Nnunet) was retrained to obtain automatic detection focused on HCC. An implementation was added to automatically extract radiomics features from the tumoral, peritumoral (among 5mm from the tumor margin) and healthy liver areas in each phase. Performance comparison between manual and algorithm segmentations was measured by intersection over union (Jaccard Index). Data obtained were explored and principal component analysis (PCA) was performed to reduce the dimensions of the dataset, keeping only the PC’s explaining 95% of the variability. After normalization, data were divided between training (70%) and test (30%) sets. Random-Forest (RF), fully connected MLP Artificial neural network (neuralnet) and extreme gradient boosting (XGB) models were fitted to predict MVI. Hyperparameters tuning was made per each model to reduce the out-of-bag error. Prediction accuracy was estimated in the test set and employed as the study end-point.
Results. Between 2008 and 2022, 218 consecutive preoperative CT scans of patients affected by HCC and submitted to surgery were collected with the relative clinical data. At the histological specimen, 72 (33.02%) patients had MVI. The Jaccard index between manual and algorithm segmentations was overall 90%. First and second order radiomics features were extracted, obtaining 672 variables per patient. After data exploration, PCA selected 58 dimensions explaining >95% of the variance. After standardization and normalization, RF, neuralnet and XGB were fitted to predict the presence of MVI. Tuning parameters were: 1) RF: n.tree=500, mtry=30; 2) Neuralnet: 2 hidden layer with 40 and 20 neurons, learning rate= 0.001, threshold for termination= 1%, activation function= sigmoid; 3) XGB: nrounds = 100, max_depth = 3, eta = 0.3. The models were then fitted in the testset to estimate prediction accuracy by confusion-matrix. RF was the best performer (Acc=98.4%, 95%CI: 0.91-0.99, Sens: 95.2%, Spec: 100%, PPV: 100% and NPV: 97.7%, fig.2).
Conclusion. Our model allowed an impressive prediction accuracy of the presence of MVI at the time of HCC diagnosis, never reached until now. This could lead to change the treatment allocation, the surgical extension and the follow-up strategy for those patients. The algorithm will be freely distributed online for medical purpose.
Fig.1 The steps of the study. From 3-phases CT scans, automatic segmentation of the liver and the tumor were obtained by a modified Nnunet. Automatic radiomics features extraction were obtained, and 3 models (RF, ANN and XGB) were fitted to predict MVI.

Fig.1 The steps of the study. From 3-phases CT scans, automatic segmentation of the liver and the tumor were obtained by a modified Nnunet. Automatic radiomics features extraction were obtained, and 3 models (RF, ANN and XGB) were fitted to predict MVI.

Fig.2 confusion matrices per each model investigated, reporting the accuracy and the number of true and false positive and negative cases identified.

Fig.2 confusion matrices per each model investigated, reporting the accuracy and the number of true and false positive and negative cases identified.

Introduction:
Obesity has a strong association with cancer; however, there is scarce literature of the protective effects of bariatric surgery (BSx) for de novo cancer. We aimed to assess whether BSx has a protective effect against de novo cancers in patients with obesity.

Methods:
Retrospective cohort study (2002-2022) using TriNetX (Cambridge, MA), a multi-institutional database from 47 US healthcare-organizations, containing >107 million patients. Adults with BMI >35 were identified by ICD-10-CM coding. History of BSx (sleeve gastrectomy, gastric bypass, and gastric band) was determined by ICD-10CM coding. Patients with history of prior malignancy, peptic ulcer disease, or ascites were excluded. Propensity score matching was performed for demographics, Elixhauser comorbidity-index, hormone therapy, and cancer screening modalities. We utilized the International Agency for Research on Cancer to determine cancers with sufficient evidence to be considered associated with obesity: esophageal adenocarcinoma, multiple myeloma, and cancers of the kidney, colon, rectum, stomach, liver, gallbladder, pancreas, ovary, endometrium, breast, and thyroid. Assessment for de novo cancer diagnosis started 1 year after index date: time of BSx (study group) or obesity diagnosis (nonsurgical control group) to minimize impact of preexisting cancers. All patients required at least 12 months of follow up designated by at least one visit after one year from index date, and patients followed up to 10 years from index date.

Results:
We initially identified 60,285 patients in the BSx group and 1,570,440 patients in nonsurgical control group (Table 1). After propensity score matching, we included 55,789 patients in each cohort. The cumulative incidence of obesity associated de novo cancers at 10 years was 4.0% (2,206 patients) in the BSx group and 8.9% (4,960 patients) in the nonsurgical control group (HR 0.482 [95% CI 0.459-0.507]; p <0.001). BSx group had lower prevalence rates for de novo breast cancer (HR 0.753 [CI 0.678-0.836]), colon cancer (HR 0.638 [CI 0.541-0.752]), liver cancer (HR 0.370 [CI 0.345-0.396]), pancreatic cancer (HR 0.84 [CI 0.569-1.080]), ovarian cancer (HR 0.654 [CI 0.531-0.806]), and endometrial cancer (HR 0.448 [CI 0.362-0.556]) when compared to nonsurgical control group (all p-values <0.05) (Table 2).

Conclusion:
Bariatric surgery significantly decreases the risk of de novo cancers in patients with obesity. We noted a protective effect of BSx with a lower cumulative incidence of all obesity associated cancers at 10 year follow up in addition to lower prevalence rate of de novo breast, colon, liver, pancreatic, ovarian, and endometrial cancers. This study supports the importance of treating obesity with bariatric surgery to reduce societal and economic burden of cancer.
Table 1: Characteristics of Patients at Baseline

Table 1: Characteristics of Patients at Baseline

Table 2: 10 Year Prevalence Rates of Cancer in Bariatric Surgery and Nonsurgical Control Groups

Table 2: 10 Year Prevalence Rates of Cancer in Bariatric Surgery and Nonsurgical Control Groups

Background:
The concept of “experience” in surgery remains nebulous and multifactorial, encompassing both the surgeon and the institution as pivotal variables. While a surgeon’s career volume seems to be a determinant in improving outcomes for pancreatoduodenectomy (PD), the influence of individual surgeon experience within high-volume institutional settings remains undefined. Within such a framework, the present investigation analyzes the association of cumulative surgeon volume experience with risk-adjusted postoperative outcomes after PDs.

Methods:
A total of 8,189 PDs performed by 82 surgeons at 18 international institutions (median:140 PD/year) were accrued from 2003 to 2020. Surgeon’s cumulative PD volume was categorized in 4 quartiles (≤150, 151 to 285, 286 to 525 and ≥526 PDs). Associations of categorical and continuous variables were analyzed with appropriate univariate tests. Fistula Risk Score (FRS)-stratified performance comparisons of postoperative outcomes across each volume quartile were quantified through multivariable analyses. Next, the same methodology was implemented when considering the ten most impactful scenarios (previously defined as a combination of occurrence and severity) for the development of clinically relevant pancreatic fistula (CR-POPF; n = 2,830 patients).

Results:
Within the overall cohort, 18.7% patients suffered severe complications (Accordion≥3), 14% developed CR-POPF, 4.8% were reoperated upon, and 2.2% expired. Surgeons performed a median of 68.5 career PDs (IQR 21-136), with a median FRS of 4 (IQR 3-5). When compared with those with less experience, the top-quartile surgeons more often operated on intermediate/high FRS cases (73% vs 61%, p <0.001); yet, their performance was associated with significant declines in CR-POPF, severe complications, reoperations, and length of stay (8 vs 9 d), whereas mortality and failure-to-rescue were not affected (Figure). This same outcome profile was accentuated even more when considering the most frequent and impactful FRS scenarios that surgeon encounter. In the overall cohort, risk-adjusted models indicate male gender, increasing age, ASA class and FRS, but not surgeon experience, as predictors for severe complications, failure-to-rescue and mortality. Instead, in advanced fistula risk circumstances, upper-echelon experience demonstrates significant reductions in CR-POPF, reoperations and LOS (Table).

Conclusion:
At specialty institutions, mortality and failure-to-rescue depend primarily on baseline patient and systemic characteristics, while cumulative surgical experience independently impacts pancreatic fistula occurrence and its attendant effects - even more so for riskier PDs. These data suggest an extended learning curve exists for this operation and reinforce the notion that surgeon experience is a key contributor for outcome improvement.
Outcomes of pancreatoduodenectomy based on individual surgeon’s experience.

Outcomes of pancreatoduodenectomy based on individual surgeon’s experience.

Surgical outcomes of pancreatoduodenectomy for the top-quartile experienced surgeons (n = 12).

Surgical outcomes of pancreatoduodenectomy for the top-quartile experienced surgeons (n = 12).


Tracks

Related Products

Thumbnail for DISSECTING THE ROLE OF NODAL METASTASES LOCATION IN PANCREATODUODENECTOMY AFTER NEOADJUVANT TREATMENT FOR CANCER: RESULTS FROM A PROSPECTIVE LYMPHADENECTOMY PROTOCOL
DISSECTING THE ROLE OF NODAL METASTASES LOCATION IN PANCREATODUODENECTOMY AFTER NEOADJUVANT TREATMENT FOR CANCER: RESULTS FROM A PROSPECTIVE LYMPHADENECTOMY PROTOCOL
IMPORTANCE: Guidelines recommend surgical exploration in selected patients with locally advanced pancreatic cancer (LAPC) following induction chemotherapy…
Thumbnail for IMMUNOREACT 8: IMMUNE MARKERS AS PREDICTORS OF LOCAL TUMOR SPREAD IN PATIENTS UNDERGOING TRANSANAL EXCISION FOR RECTAL CANCER
IMMUNOREACT 8: IMMUNE MARKERS AS PREDICTORS OF LOCAL TUMOR SPREAD IN PATIENTS UNDERGOING TRANSANAL EXCISION FOR RECTAL CANCER
LUNCH AND TRAINEE JEOPARDY! 12:00 PM - 1:00 PM LEADERSHIP FORUM, NETWORKING SESSION AND ROUNDTABLES 4:00 PM - 5:30 PM KEYNOTE ADDRESS: FUTURE SCENARIO PLANNING TO PREDICT THE FUTURE OF SURGERY 4:00 PM - 4:30 PM
Thumbnail for KEYNOTE ADDRESS: FUTURE SCENARIO PLANNING TO PREDICT THE FUTURE OF SURGERY
KEYNOTE ADDRESS: FUTURE SCENARIO PLANNING TO PREDICT THE FUTURE OF SURGERY
LUNCH AND TRAINEE JEOPARDY! 12:00 PM - 1:00 PM LEADERSHIP FORUM, NETWORKING SESSION AND ROUNDTABLES 4:00 PM - 5:30 PM KEYNOTE ADDRESS: FUTURE SCENARIO PLANNING TO PREDICT THE FUTURE OF SURGERY 4:00 PM - 4:30 PM
Thumbnail for CLINICO-MORPHOLOGICAL CORRELATION OF RESECTED PANCREATIC DUCTAL ADENOCARCINOMA AFTER NEOADJUVANT TREATMENT
CLINICO-MORPHOLOGICAL CORRELATION OF RESECTED PANCREATIC DUCTAL ADENOCARCINOMA AFTER NEOADJUVANT TREATMENT
Pancreatic ductal adenocarcinoma (PDAC) exists in several morphological subtypes differing in prognostic significance. However, to date, a clinico-morphological correlation of these subtypes in the context of neoadjuvant therapy (NAT) has not been performed…